Otsuka

Otsuka's Taiho pays $400M for Swiss partner to 'turbocharge' 3 ADCs to clinic
Fierce Biotech
Mon, 03/17/25 - 11:09 am
Otsuka
Taiho Pharmaceutical
M&A
Araris Biotech
Otsuka breaks up with cancer candidates on strategic grounds
Fierce Biotech
Fri, 02/14/25 - 09:22 am
Otsuka
cancer
CAR-T
Japan's Otsuka Pharma & ICU Medical sign $200 M deal to create joint venture in North America for manufacturing IV solutions
BioSpectrum Asia
Wed, 11/13/24 - 11:08 am
Otsuka
ICU Medical
IVs
Otsuka eyes early filing of IgAN drug after phase 3 readout
Pharmaphorum
Tue, 10/22/24 - 11:19 am
Otsuka
anti-APRIL
sibeprenlimab
IgA nephropathy
clinical trials
Abilify Asimtufii campaign uses 3D CGI to detail journey of bipolar I patients
Medical Marketing and Media
Mon, 09/9/24 - 07:14 pm
pharma marketing
DTC advertising
Ability Asimtufii
Otsuka
Lundbeck
Otsuka Pays Up to $1.1B to Buy Jnana, Adds Drug Discovery Capabilities
BioSpace
Thu, 08/1/24 - 11:26 am
Otsuka
M&A
Jnana Therapeutics
drug discovery
Why Otsuka launched a digital health company
Medical Marketing and Media
Mon, 06/10/24 - 11:13 am
Otsuka
Otsuka Precision Health
Medtech
digital therapeutics
major depressive disorder
Otsuka defies digital health downturn with new company
BioPharma Dive
Thu, 05/30/24 - 11:07 am
Otsuka
Medtech
digital health
major depressive disorder
Otsuka Precision Health
Otsuka and Lundbeck report data from three PTSD treatment trials
Clinical Trials Arena
Wed, 05/29/24 - 11:52 am
Otsuka
Lundbeck
PTSD
clinical tirals
brexpiprazole-sertraline
Otsuka Drops Alzheimer’s Agitation Drug Following Phase III Failure
BioSpace
Wed, 05/22/24 - 11:20 am
Otsuka
Alzheimer's disease
Alzheimer's agitation
clinical trials
AVP-786
3 patent expirations in 2024 and how companies are pivoting
Pharma Voice
Wed, 04/17/24 - 11:13 am
patents
patent cliff
Bayer
J&J
Xarelto
Novo Nordisk
Victoza
Otsuka
Lundbeck
Abilify
Otsuka Drug Candidate Fails Phase III Alzheimer’s Agitation Study
BioSpace
Tue, 02/13/24 - 11:27 am
Otsuka
clinical trials
AVP-786
Alzheimer's agitation
FDA rules Otsuka marketing claim overstates Rexulti efficacy, threatening cornerstone of huge TV push
Fierce Pharma
Tue, 11/14/23 - 11:19 am
Otsuka
FDA
Rexulti
pharma marketing
clinical depression
Otsuka reports positive data from two Phase III ADHD treatment trials
Clinical Trials Arena
Mon, 10/30/23 - 11:44 am
Otsuka
clinical trials
ADHD
centanafadine
Otsuka, Shape Ink Potential $1.5B Deal to Develop Eye AAV Gene Therapies
BioSpace
Fri, 09/8/23 - 10:11 am
Otsuka
Shape Therapeutics
gene therapy
AAV gene therapy
RNA editing
ocular diseases
Evaluating renal denervation rivals, FDA advisory panel backs ReCor, shuns Medtronic
Fierce Biotech
Fri, 08/25/23 - 09:51 am
Medtech
FDA
renal denervation
Otsuka
Recor
Medtronic
hypertension
Sumitomo, Otsuka’s Schizophrenia Candidate Fails Phase III Trials
BioSpace
Mon, 07/31/23 - 09:50 pm
Sumitomo Pharma
Otsuka
clinical trials
ulotaront
schizophrenia
Hope springs for April inhibition
EP Vantage
Tue, 06/13/23 - 10:27 am
Novartis
Chinook Therapeutics
April inhibition
M&A
Vera Therapeutics
Otsuka
RemeGen
Alpine Immune Sciences
Akso Biopharmaceutical
Aurinia Pharmaceuticals
Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation
Yahoo/Benzinga
Thu, 05/11/23 - 08:53 pm
Otsuka
Lundbeck
FDA
Rexulti
Alzheimer's agitation
Otsuka, Lundbeck gain FDA nod for longer-acting version of schizophrenia drug Abilify
Fierce Pharma
Mon, 05/1/23 - 10:04 am
Otsuka
Lundbeck
FDA
Abilify
Asimtufii
bipolar disorder

Pages